Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 19, 2020

Primary Completion Date

January 6, 2021

Study Completion Date

January 6, 2021

Conditions
Spinal Cord Injury
Interventions
BIOLOGICAL

MT-3921 Low dose

MT-3921 Low dose, intravenous, single dosing

Trial Locations (13)

19107

Thomas Jefferson University, Philadelphia

23298

VA Commonwealth Univ. School of Medicine, Richmond

27834

Vidant Medical Center, Greenville

28203

Carolinas Healthcare System / Atrium Health, Charlotte

39216

University of Mississippi Medical Center, Jackson

43210

The Ohio State University Wexner Medical Center, Columbus

48109

University of Michigan, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

60611

Northwestern University / Shirley Ryan Ability LAB (SRALAB), Chicago

61801

Carle Foundation Hospital, Urbana

63110

Washington University School of Medicine, St Louis

87131

University of New Mexico Hospital, Albuquerque

95816

UC Davis Medical Center, Sacramento

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma America Inc.

INDUSTRY